Patent ID: 6077846
Filing Date: 2000-06-20
Classification: A61K,A61P

Abstract:
A method for treating a disease that can be treated with a nicotinic agonist comprising administering an effective amount of a 7-azabicyclo-heptane or heptene compound having the formula: ##STR11## wherein: R.sup.1 and R.sup.4 are independently selected from the group consisting of hydrogen; alkyl; alkylhydroxy; alkyloxyalkyl; alkylthioalkyl; alkylamino; oxyalkyl; carboalkoxy, alkyl; aryl; thioalkyl; and Q;each R.sup.3, R.sup.5 and R.sup.6 may be independently selected from the group consisting of hydrogen; alkyl; alkylhydroxy; alkyloxyalkyl; alkylthioalkyl; alkylaminoalkyl; oxyalkyl; thioalkyl; halo; --CF.sub.3 ; --NH.sub.2 ; alkylamino; dialkylamino; --CO.sub.2 H; --CO.sub.2 -alkyl; --C(O)alkyl; --CH; --C(O)NH.sub.2 ; --C(O)NH(alkyl); --C(O)N(alkyl).sub.2 ; alkyl; and --SO.sub.n (alkyl), --SO,(aryl), --SO.sub.n (heteroaryl), wherein n=0, 1 or 2;R.sup.5 and R.sup.6 together can be alkylidene or haloalkylidene;each R.sup.2 may be independently selected from the group consisting of hydrogen, alkyl; --CH.sub.2 --; HC.dbd.CH.sub.2 ; alklhydroxy; alkyloxyalkl; alkylamine; caboxylate, --CH; Q; --C(O)Q; and -alkyl(Q);wherein Q is selected from the group consisting of: ##STR12## and wherein the Q moiety can be optionally substituted with from 1 to 3 substituent groups W;wherein each substituent group W is selected from the group consisting of alkyl; halo; heteroaryl; --OH; oxyalkyl; --SH; thioalkyl; --SO(alky); --SO.sub.2 (alkyl); --OCH.sub.2 CH.dbd.CH.sub.2 ; --OCH.sub.2 (C.sub.6 H.sub.5); --CF.sub.3 ; --CN; alkylenedioxy; --CO.sub.2 H; --CO.sub.2 alkyl; --OCH.sub.2 CH.sub.2 OH; --NO.sub.2 ; --NH.sub.2 ; --NH(alkyl); --N(alkyl)2; --NCH(O)alkyl; --SO.sub.2 CF.sub.3 ; and --NHCH.sub.2 aryl;R.sup.7 is selected from the group consisting of hydrogen; alkyl; --CH.sub.2 --(cycloalkyl); --CH.sub.2 CH.dbd.CH.sub.2 ; --CH.sub.2 CH.sub.2 (C.sub.6 H.sub.5); alkylhydroxy; alkylanino(alkyl).sub.0-2 ; alkoxyalkyl; alkylthioalkyl; and aryl; and Q;wherein the lines--represent optional double bonds in the formula; and pharmaceutically acceptable derivatives and salts thereof.